ClinicalTrials.gg
CompletedNCT00787150Updated May 1, 2013Results posted

A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

A Phase 2 interventional study of Apixaban and Apixaban in Atrial Fibrillation, sponsored by Pfizer. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-05-01.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Enrollment
19th of 31
222 · median 586
Started
2008
the only one that year
Phase 2
4 of 31
1 open now
Registered
3rd of 31
by date
Lead sponsor
2 of 31
Pfizer

Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 19th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 2, and was the 3rd registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 20 years outpatient (regardless of sex)
  • Patients diagnosed as non-valvular atrial fibrillation (NVAF)
  • One or more following risks of stroke.

Exclusion criteria

Exclusion Criteria:

  • Recent cerebral infarction (includes ) within 4 weeks of week 0.
  • Subjects who have or are suspected to have a serious/hereditary bleeding tendency, such as disseminated intravascular coagulation syndrome (DIC), congenital dysfunction and von Willebrand disease (those suspected from the family history are included).
  • Subjects who have or are suspected to have a serious/hereditary thrombogenic tendency (those suspected from the family history are included) or those who require continuation of the Warfarin therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Apixaban 5mg BID

    Drug: Apixaban

  • Experimental
    Apixaban 2.5mg BID

    Drug: Apixaban

  • Active comparator
    Warfarin

    Drug: Warfarin sodium

Interventions

  • Apixaban 5 mg tablet BID for 12 weeks

  • Apixaban 2.5 mg tablet BID for 12 weeks

  • At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period

    Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Number of Participants With Total Bleeding Events During the Treatment Period

    Total bleeding events consisted of major (per International Society on Thrombosis and Haemostasis \[ISTH\] Criteria), clinically relevant non-major and minor bleeding events. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding were classified as minor bleeding.

    Time frame: Baseline to Week 12

  2. Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period

    Major bleeding event is acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding is also major bleeding event.

    Time frame: Baseline to Week 12

  3. Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period

    Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

    Time frame: Baseline to Week 12

  4. Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period

    The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

    Time frame: Baseline to Week 12

  5. Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period

    The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

    Time frame: Baseline to Week 12

  6. Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period

    The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

    Time frame: Baseline to Week 12

Other outcomes

  1. Mean Plasma Apixaban Concentration at Each Time Point in Participants Treated With Apixaban

    Sample at 4 hours postdose was to be taken if possible.

    Time frame: 0, 2, 4 hours postdose at Week 1 and Week 8

  2. Mean Prothrombin Time (PT) at Each Time Point in Participants Treated With Apixaban

    Sample at 4 hours postdose was to be taken if possible.

    Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8

  3. Mean Prothrombin Time-International Normalized Ratio (PT-INR) at Each Time Point in Participants Treated With Apixaban

    Blood sample at 4 hours postdose was collected if possible. PT-INR is a standardized measure derived from prothrombin time (PT). The systematic variations in PT assay results are corrected in PT-INR in order to optimize measurements of vitamin K antagonists.

    Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8

  4. Mean Activated Partial Thromboplastin Time (aPTT) at Each Time Point in Participants Treated With Apixaban

    Blood Sample at 4 hours postdose was collected if possible. The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects.

    Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8

  5. Mean Anti-Xa Activity (Apixaban Units) at Each Time Point in Participants Treated With Apixaban

    Blood sample at 4 hours postdose was collected if possible. Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not be calculated. Therefore, 0 means not calculated.

    Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8

  6. Mean Prothrombin Fragment 1+2 (F1+2) at Each Time Point in Participants Treated With Warfarin or Apixaban

    Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not calculated. Therefore, 0 indicates not calculated.

    Time frame: Week 0, Week 1, Week 8

  7. Mean D-Dimer at Each Time Point in Participants Treated With Warfarin or Apixaban

    Below the limit of quantification (BLQ) was assigned the value 0 for calculation.

    Time frame: Week 0, Week 1, Week 8

07

Results

Posted Mar 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Started757271
Completed666566
Not completed975
Withdrew: Adverse event444
Withdrew: Physician decision121
Withdrew: Withdrawal by subject210
Withdrew: Dosing incorrect study durg200

Outcome measures

PrimaryNumber of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period

Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period411
SecondaryNumber of Participants With Total Bleeding Events During the Treatment Period

Total bleeding events consisted of major (per International Society on Thrombosis and Haemostasis \[ISTH\] Criteria), clinically relevant non-major and minor bleeding events. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding were classified as minor bleeding.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Total Bleeding Events During the Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Total Bleeding Events During the Treatment Period13917
SecondaryNumber of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period

Major bleeding event is acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding is also major bleeding event.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period100
SecondaryNumber of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period

Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period311
SecondaryNumber of Participants With Stroke or Systemic Embolism During the Intended Treatment Period

The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period300
SecondaryNumber of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period

The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period300
SecondaryNumber of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period

The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period
participantsWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period000
Other pre-specifiedMean Plasma Apixaban Concentration at Each Time Point in Participants Treated With Apixaban

Sample at 4 hours postdose was to be taken if possible.

Time frame:
0, 2, 4 hours postdose at Week 1 and Week 8
Reported as:
Mean · ng/mL
Mean Plasma Apixaban Concentration at Each Time Point in Participants Treated With Apixaban
ng/mLApixaban 2.5mg BIDApixaban 5.0 mg BID
0 hour post dose at Week 1 (n=68, 70)53.31 ± 28.55119.34 ± 50.83
2 hours post dose at Week 1 (n=68, 70)99.43 ± 44.65201.80 ± 95.58
4 hours post dose at Week 1 (n=38, 35)104.09 ± 44.48224.40 ± 77.06
0 hour post dose at Week 8 (n=67, 66)62.83 ± 37.27137.79 ± 54.91
2 hours post dose at Week 8 (n=67, 66)120.16 ± 57.79250.53 ± 81.35
4 hours post dose at Week 8 (n=35, 29)110.58 ± 49.96244.55 ± 84.27
Other pre-specifiedMean Prothrombin Time (PT) at Each Time Point in Participants Treated With Apixaban

Sample at 4 hours postdose was to be taken if possible.

Time frame:
Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Reported as:
Mean · second
Mean Prothrombin Time (PT) at Each Time Point in Participants Treated With Apixaban
secondApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=72, 71)14.54 ± 2.2014.41 ± 2.06
0 hour post dose at Week 1 (n=67, 70)12.22 ± 1.5612.54 ± 0.79
2 hours post dose at Week 1 (n=68, 70)12.46 ± 0.7213.28 ± 1.05
4 hours post dose at Week 1 (n=38, 35)12.36 ± 0.6713.48 ± 0.82
0 hour post dose at Week 8 (n=67, 66)12.09 ± 0.7312.74 ± 0.87
2 hours post dose at Week 8 (n=67, 66)12.68 ± 0.8213.83 ± 1.03
4 hours post dose at Week 8 (n=35, 29)12.47 ± 0.7513.85 ± 1.07
Other pre-specifiedMean Prothrombin Time-International Normalized Ratio (PT-INR) at Each Time Point in Participants Treated With Apixaban

Blood sample at 4 hours postdose was collected if possible. PT-INR is a standardized measure derived from prothrombin time (PT). The systematic variations in PT assay results are corrected in PT-INR in order to optimize measurements of vitamin K antagonists.

Time frame:
Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Reported as:
Mean · International normalized ratio
Mean Prothrombin Time-International Normalized Ratio (PT-INR) at Each Time Point in Participants Treated With Apixaban
International normalized ratioApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=72, 71)1.76 ± 0.461.72 ± 0.43
0 hour post dose at Week 1 (n=67, 70)1.30 ± 0.371.34 ± 0.15
2 hours post dose at Week 1 (n=68, 70)1.33 ± 0.141.48 ± 0.21
4 hours post dose at Week 1 (n=38, 35)1.30 ± 0.121.51 ± 0.18
0 hour post dose at Week 8 (n=67, 66)1.27 ± 0.141.38 ± 0.17
2 hours post dose at Week 8 (n=67, 66)1.37 ± 0.161.61 ± 0.20
4 hours post dose at Week 8 (n=35, 29)1.34 ± 0.151.59 ± 0.22
Other pre-specifiedMean Activated Partial Thromboplastin Time (aPTT) at Each Time Point in Participants Treated With Apixaban

Blood Sample at 4 hours postdose was collected if possible. The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects.

Time frame:
Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Reported as:
Mean · Second
Mean Activated Partial Thromboplastin Time (aPTT) at Each Time Point in Participants Treated With Apixaban
SecondApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=72, 71)34.51 ± 5.0532.98 ± 4.39
0 hour post dose at Week 1 (n=67, 70)33.26 ± 10.2433.24 ± 4.28
2 hours post dose at Week 1 (n=68, 70)33.04 ± 3.5735.19 ± 4.42
4 hours oist dose at Week 1 (n=38, 35)32.00 ± 3.4935.36 ± 5.44
0 hour post dose at Week 8 (n=67, 66)33.83 ± 5.1835.65 ± 4.32
2 hours post dose at Week 8 (n=67, 66)34.67 ± 4.3937.92 ± 4.78
4 hours post dose at Week 8 (n=35, 29)32.75 ± 3.8636.46 ± 5.19
Other pre-specifiedMean Anti-Xa Activity (Apixaban Units) at Each Time Point in Participants Treated With Apixaban

Blood sample at 4 hours postdose was collected if possible. Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not be calculated. Therefore, 0 means not calculated.

Time frame:
Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Reported as:
Mean · ng/mL
Mean Anti-Xa Activity (Apixaban Units) at Each Time Point in Participants Treated With Apixaban
ng/mLApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=72, 71)0 ± 00 ± 0
0 hour post dose at Week 1 (n=68, 69)45.29 ± 26.77111.19 ± 49.02
2 hours post dose at Week 1 (n=68, 70)94.90 ± 45.23187.58 ± 85.72
4 hours post dose at Week 1 (n=38, 35)99.07 ± 44.46213.24 ± 67.54
0 hour post dose at Week 8 (n=67, 65)56.81 ± 37.34130.12 ± 52.20
2 hours post dose at Week 8 (n=67, 66)114.97 ± 56.25236.36 ± 88.08
4 hours post dose at Week 8 (n=35, 29)103.61 ± 44.54237.78 ± 78.58
Other pre-specifiedMean Prothrombin Fragment 1+2 (F1+2) at Each Time Point in Participants Treated With Warfarin or Apixaban

Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not calculated. Therefore, 0 indicates not calculated.

Time frame:
Week 0, Week 1, Week 8
Reported as:
Mean · pmol/L
Mean Prothrombin Fragment 1+2 (F1+2) at Each Time Point in Participants Treated With Warfarin or Apixaban
pmol/LWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=75, 72, 71)144.0 ± 345.20 ± 091.4 ± 115.3
Week 1 (n=75, 68, 70)100.4 ± 139.0133.8 ± 105.5137.0 ± 255.5
Week 8 (n=68, 67, 66)0 ± 0152.9 ± 79.7121.1 ± 56.3
Other pre-specifiedMean D-Dimer at Each Time Point in Participants Treated With Warfarin or Apixaban

Below the limit of quantification (BLQ) was assigned the value 0 for calculation.

Time frame:
Week 0, Week 1, Week 8
Reported as:
Mean · ng/mL
Mean D-Dimer at Each Time Point in Participants Treated With Warfarin or Apixaban
ng/mLWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Week 0 (n=75, 72, 71)240.4 ± 333.5297.8 ± 634.6196.4 ± 181.4
Week 1 (n=75, 68, 70)245.2 ± 325.7209.9 ± 202.6237.0 ± 314.3
Week 8 (n=68, 67, 66)209.9 ± 201.1227.0 ± 253.5203.5 ± 190.6

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Warfarin—4/75 (5.3%)17/75 (22.7%)
Apixaban 2.5mg BID—1/72 (1.4%)24/72 (33.3%)
Apixaban 5.0 mg BID—5/71 (7%)22/71 (31%)
Most frequent serious events
Most frequent serious events
EventWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
Cerebral infarctionNervous system disorders2/750/720/71
Accidental overdoseInjury, poisoning and procedural complications1/750/721/71
OverdoseInjury, poisoning and procedural complications0/750/721/71
HypoglycaemiaMetabolism and nutrition disorders0/750/721/71
Back painMusculoskeletal and connective tissue disorders0/750/721/71
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/750/721/71
Benign prostatic hyperplasiaReproductive system and breast disorders0/750/721/71
Arterial stenosis limbVascular disorders0/751/720/71
Subarachnoid haemorrhageNervous system disorders1/750/720/71
Most frequent other events
Showing 10 of 16
Most frequent other events
EventWarfarinApixaban 2.5mg BIDApixaban 5.0 mg BID
NasopharyngitisInfections and infestations7/758/728/71
EpistaxisRespiratory, thoracic and mediastinal disorders4/754/724/71
Blood urine presentInvestigations4/751/723/71
DiarrhoeaGastrointestinal disorders0/753/721/71
Atrial fibrillationCardiac disorders0/750/722/71
Oedema peripheralGeneral disorders0/750/722/71
ContusionInjury, poisoning and procedural complications1/750/722/71
FallInjury, poisoning and procedural complications0/750/722/71
Blood creatine phophkinase increasedInvestigations0/752/722/71
HaematuriaRenal and urinary disorders1/750/722/71

Baseline characteristics

Age Continuous
Age Continuous(years)WarfarinApixaban 2.5mg BIDApixaban 5.0 mg BIDTotal
Mean71.7 ± 7.069.3 ± 8.470.0 ± 8.170.3 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)WarfarinApixaban 2.5mg BIDApixaban 5.0 mg BIDTotal
Female14111338
Male606361184
08

Study locations

18 sites
  • Pfizer Investigational Site
    Nagoya, Aichi, Japan
  • Pfizer Investigational Site
    Seto, Aichi, Japan
  • Pfizer Investigational Site
    Touon, Ehime, Japan
  • Pfizer Investigational Site
    Kitakyushu, Fukuoka, Japan
  • Pfizer Investigational Site
    Ogaki, Gifu, Japan
  • Pfizer Investigational Site
    Isezaki, Gunma, Japan
  • Pfizer Investigational Site
    Shibukawa, Gunma, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Higashiibaraki-gunn Ibarakimachi, Ibaraki, Japan
  • Pfizer Investigational Site
    Zentsuji, Kagawa, Japan
  • Pfizer Investigational Site
    Kawasaki, Kanagawa, Japan
  • Pfizer Investigational Site
    Tsu, Mie, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Iwakuni, Yamaguchi, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
  • Pfizer Investigational Site
    Kumamoto, Japan
09

References and documents

Publications

  • Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-. Circ J. 2011;75(8):1852-9. doi: 10.1253/circj.cj-10-1183. Epub 2011 Jun 14. PubMed 21670542 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2008
First posted
Nov 7, 2008
Start
Jun 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Mar 6, 2013
Last update
May 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00787150
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 7, 2008
Start date
Jun 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Mar 6, 2013
Last update
May 1, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion